Failed 2018

    Theranos

    Silicon Valley 'fake it till you make it' collapses on contact with regulated healthcare — biological reality does not bend to press releases.

    TL;DR — Failure Post-Mortem

    Theranos was a HealthTech/Biotech startup founded in 2003 in USA. It raised $945M before collapsing in 2018 — 15 years of runway burned. IdeaProof's AI Failure Score: 53/100, driven by fraud & technology that never worked. The shutdown affected employees, investors, and the broader HealthTech/Biotech ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did Theranos fail?

    Theranos failed in 2018 after 15 years of operation, losing $945M in raised capital. The root cause was fraud & technology that never worked. Key lesson: Silicon Valley 'fake it till you make it' collapses on contact with regulated healthcare — biological reality does not bend to press releases.

    Verifiable facts
    Sourced
    Founded → Closed

    2003 → 2018

    Funding Raised

    $945M

    Industry

    HealthTech/Biotech

    Country

    USA

    IdeaProof AI Failure Score

    53/100
    Market Fit Risk
    0
    Burn Rate Risk
    60
    Founder Risk
    100

    What Happened: The Timeline

    🚀

    2003

    Founded by 19-year-old Elizabeth Holmes after dropping out of Stanford

    📈

    2013-09

    Launches partnership with Walgreens

    📈

    2014

    Peak $9B valuation after $400M round

    ⚠️

    2015-10-16

    WSJ investigation by John Carreyrou published

    ⚠️

    2016

    CMS revokes lab certification; voids two years of test results

    📉

    2018-03

    SEC charges Holmes with 'massive fraud'

    💀

    2018-09

    Company formally dissolves

    💀

    2022-01-03

    Holmes convicted on 4 counts of investor fraud

    💀

    2022-11-18

    Holmes sentenced to 11 years 3 months in prison

    Root Causes

    Theranos raised ~$945M from a who's-who of private investors while claiming its 'Edison' device could run 200+ blood tests from a finger-prick sample. Elizabeth Holmes was celebrated on magazine covers as Silicon Valley's youngest self-made female billionaire at a $9B peak valuation. An October 2015 Wall Street Journal investigation by John Carreyrou revealed the technology didn't work: most tests were secretly run on modified Siemens machines with diluted samples, producing unreliable results for actual patients. The SEC charged Holmes with fraud in 2018 and the company dissolved. In January 2022 she was convicted on 4 counts of investor fraud and sentenced to 11 years and 3 months in federal prison; former president Sunny Balwani received nearly 13 years.

    Causal Chain

    Curated · IdeaProof interpretation

    This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.

    Root cause

    The core Edison analyzer never met the clinical accuracy required for its marketed use cases; the gap between claim and reality was concealed rather than fixed.

    Contributing factors
    • Founder-CEO cult of secrecy blocked independent scientific review
    • Board composed of political figures without diagnostics expertise
    • Commercial deployment at Walgreens before validation
    Proximate cause

    Oct 15, 2015 WSJ investigation (John Carreyrou) exposed test-accuracy failures.

    Terminal event

    Company dissolved Sep 2018; founder convicted of wire fraud Jan 2022.

    Base rates

    External sources

    A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Theranos's profile. Sources are third-party; we do not restate them as our own claims.

    <3%
    reason

    of failures involve prosecutable fraud, but these cases account for a disproportionate share of investor losses and media coverage.

    IdeaProof analysis of court filings 2015–2024 (2024)
    ~97%
    industry

    of venture-backed consumer hardware startups do not reach a profitable exit within 10 years — hardware requires atypical capital efficiency to survive.

    PitchBook Emerging Tech Research (2023)
    ~70%
    industry

    of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.

    Rock Health State of Digital Health (2023)
    ~90%
    all

    of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.

    Startup Genome / CB Insights aggregate (2024)
    ~35%
    all

    of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).

    US Bureau of Labor Statistics — BED (2024)
    ~35%
    stage

    of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.

    CB Insights Venture Capital Funnel (2023)

    After the shutdown

    Post-mortem

    Most databases stop at the shutdown date. Here is what happened next — where the founders, assets, employees, and category ended up.

    Founder(s)

    Elizabeth Holmes convicted on 4 counts of wire fraud (Jan 2022), sentenced to 11 years 3 months. Ramesh "Sunny" Balwani convicted on 12 counts, sentenced to 12 years 11 months.

    Assets & IP

    IP portfolio (~1,000 patents) sold to Fortress Investment Group in 2018 for undisclosed sum. Physical labs dissolved. Brand permanently retired.

    Investor recovery

    ~$0 for equity investors. Walgreens settled its $140M lawsuit for undisclosed terms. Rupert Murdoch, DeVos family, Cox family all wrote off investments fully.

    Category outcome

    Blood-diagnostics-from-fingerprick remains an active R&D area (Truvian, Babson Diagnostics) but no venture has attempted Theranos-scale claims post-2018.

    Legal outcome

    Criminal case closed. SEC settled with Holmes for $500K + 10-year officer/director bar.

    Key Lessons Learned

    1. Deep-tech requires proof, not narrative

    Blood testing is a regulated life-safety business. If you can't publish peer-reviewed accuracy data, you have no product.

    2. Board composition signals rigor

    Kissinger and Mattis were prestige; you needed clinicians and diagnostics scientists.

    3. Fraud starts with 'we'll figure it out later'

    Small demo shortcuts compound into criminal misrepresentations when growth outpaces the tech.

    Competitors That Won

    Quest Diagnostics

    $17B market cap, 45,000+ employees, gold standard in testing

    Why they won: Decades of proven technology, regulatory compliance, massive lab network

    Labcorp

    $20B market cap, reliable diagnostic testing

    Why they won: Incremental innovation within proven frameworks rather than "revolutionary" claims

    Frequently Asked Questions

    Sources & Confidence

    Every data point is tagged with its source type and our confidence in it. How we grade sources.

    Field Source Type Confidence
    Shutdown reason Wall Street Journal (Carreyrou) (2015-10-15)
    Reputable press
    high
    Root cause attribution IdeaProof Research
    Primary source
    high
    Additional references

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Theranos.

    Spotted a factual error?

    Approved corrections are published in the public changelog with attribution.